Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: Clinical and immunological effects

Clinical and Experimental Allergy

Volumn 39, Issue 12, 2009, Pages 1903-1909

  Ceuppens, J L ^a   Bullens, D ^a   Kleinjans, H ^b   Van Der Werf, J ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HAL Allergy BV   (Netherlands)

Author keywords

Allergoid; Birch pollen allergy; Immunotherapy; Modified allergens; SCIT

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALLERGEN; ALUMINUM HYDROXIDE; ANTIHISTAMINIC AGENT; BET V 1 ALLERGEN; BIRCH POLLEN EXTRACT; CORTICOSTEROID; GLUTARALDEHYDE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; PLACEBO; POLLEN EXTRACT; PURETHAL; STEROID; UNCLASSIFIED DRUG;

ADULT; ALLERGIC DISEASE; ALLERGIC RHINOCONJUNCTIVITIS; ARTICLE; ASTHMA; BASOPHIL; BIRCH; CELL ACTIVATION; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EYE ALLERGY; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE ALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SCORING SYSTEM; TACHYCARDIA; TREATMENT WITHDRAWAL;

ADULT; ANTIGENS, CD; ANTIGENS, PLANT; BASOPHIL DEGRANULATION TEST; BASOPHILS; BETULA; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; EYE; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NOSE; PLANT EXTRACTS; PLATELET MEMBRANE GLYCOPROTEINS; POLLEN; RESPIRATORY SYSTEM; RHINITIS, ALLERGIC, SEASONAL; SERUM; SKIN TESTS; TREATMENT OUTCOME;

EID: 72449139532     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2009.03379.x     Document Type: Article

References (27)

1. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007.
2. Malling HJ. Immunotherapy for allergic rhinoconjunctivitis. Clin Allergy Immunol 2004 18 : 495 509.
3. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment of resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 117 : 319 325.
4. Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (Suppl. 5) : 147 334.
5. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract: VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997 99 : 450 453.
6. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002 109 : 251 256.
7. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999 341 : 468 475.
8. Linneberg A, Nielsen NH, Madsen F, Frolund L, Dirksen A, Jørgensen T. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart. The Copenhagen Allergy Study. J Allergy Clin Immunol 2000 106 : 247 252. (Pubitemid 30644997)
9. Linneberg A, Gislum M, Johansen N, Hisemoen LL, Jørgensen T. Temporal trends of aeroallergen sensitization over twenty-five years. Clin Exp Allergy 2007 37 : 1137 1142.
10. Van der Zee JS, Kleinjans HAJ. Safety study with a new house dust mite (D. pteronissinus) allergoid. Allergy 2003 58 (Suppl. 74) : 219, poster abstract 754.
11. Casanovas M, Martin R, Jimenez C, Caballero R, Fernandez-Caldas E. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts. Clin Exp Allergy 2007 37 : 434 440.
12. Ariano R, Kroon AM, Augeri G, Canonica GW, Passalacqua G. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy 1999 54 : 313 319. (Pubitemid 29232386)
13. Brewczynski PZ, Kroon AM. Wirksamkeit und Verträglichkeit einer Immunotherapie mit modifizierten Gräserpollenallergenen. Ergebnisse einer plazebokontrollierten Studie. Allergologie 1999 22 : S411 20.
14. Ameal A, Vega-Chicote JM, Fernandez S et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005 60 : 1178 1183.
15. Garcia-Robaina JC, Sanchez I, de la Torre F, Fernandez-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farina in a double-blind placebo controlled study. J Allergy Clin Immunol 2006 118 : 1026 1032.
16. Petersen BN, Janniche H, Munch EP et al. Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988 43 : 353 362. (Pubitemid 18181163)
17. Bufe A, Ziegler-Kirbach E, Stoeckmann E et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004 59 : 498 504.
18. Malling HJ. Methods of skin testing. Allergy 1993 48 (Suppl. 14) : 55 6.
19. Malling HJ. Reproducibility of skin sensitivity using a quantitative skin prick test. Allergy 1985 40 : 400 404.
20. Bolhaar STHP, Tiemessen MM, Zuidmeer L et al. Efficay of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004 34 : 761 769.
21. Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998 53 : 461 472.
22. Malling HJ. Sublingual immunotherapy: efficacy - methodology and outcome of clinical trials. Allergy 2006 61 (Suppl. 81) : 24 8.
23. Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004 101 (Suppl. 2) : 14677 14682.
24. Van Neerven RJJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 T cells by inhibiting serum-IgE facilitated allergen presentation. J Immunol 1999 163 : 2944 2952.
25. Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006 6 : 761 771.
26. Müller U, Mosbech H. EAACI position paper: immunotherapy with Hymenoptera venoms. Allergy 1993 48 (Suppl. 14) : 34 46.
27. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardised, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993 91 : 709 722.